A group of multiple myeloma experts from the International Myeloma Working Group recently published a review of management strategies for drug-induced peripheral neuropathy in patients with multiple myeloma.

This Beacon article, the second in a three-part series, summarizes the experts’ recommendations for the treatment of drug-induced peripheral neuropathy.

The first article in the series describes peripheral neuropathy and summarizes the symptoms of drug-induced neuropathy as well as the risk of developing neuropathy associated with myeloma therapies.  A third article will summarize the experts’ recommendations for prevention of peripheral neuropathy as …

A group of multiple myeloma experts from the International Myeloma Working Group recently published a review of management strategies for drug-induced peripheral neuropathy in patients with multiple myeloma.

This Beacon article, the first in a three-part series describes peripheral neuropathy and summarizes the symptoms of drug-induced neuropathy as well as the risk of developing neuropathy associated with myeloma therapies.

A second Beacon article will discuss the experts’ recommendations for the treatment of drug-induced peripheral neuropathy, and a third article will summarize their recommendations for prevention of peripheral …

According to a recent Swedish study, a family history of blood clots has a greater impact on the risk of developing blood clots in multiple myeloma patients than in the general population.

“There are probably synergistic effects; i.e., if you have a family history [of blood clots] and multiple myeloma, the risk is more then the sum of the individual risks,” explained Dr. Sigurdur Kristinsson of the Karolinska University Hospital in Sweden and lead investigator of the study.

Based on the study’s findings, Dr. Kristinsson said, “Perhaps family history should be taken …

Results of a small Phase 2 study show that newly diagnosed multiple myeloma patients achieve similar response rates with alternating weeks of Revlimid and thalidomide in combination with dexamethasone as patients receiving Revlimid with dexamethasone or thalidomide with dexamethasone.

The study investigators point out that the alternating regimen was well tolerated even though Revlimid was administered at a higher than usual dose of 50 mg per day. However, the regimen was not, as they had hoped, more effective than either Revlimid (lenalidomide) or thalidomide (Thalomid) alone in combination with

The results of a small Phase 2 study indicate that sequential mainte­nance therapy involving six months of Velcade followed by six months of thalidomide is both effective and tolerable in multiple myeloma patients who have received a stem cell transplant.

The Phase 2 trial was carried out recently at the City of Hope National Medical Center in Duarte, California.

Many patients in the trial experienced peripheral neuropathy (nerve damage that causes pain and tingling in the extremities).

However, the City of Hope researchers believe a key result of their study is that …

A group of myeloma experts from the International Myeloma Working Group recently published a consensus statement on maintenance therapies for myeloma patients.

In their statement, the experts reviewed the main findings from previous clinical trials that investigated the impact of maintenance therapies containing the novel agents thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib).

Maintenance therapy is a prolonged, and often low-dose, form of treatment given to myeloma patients after their initial therapy. The goal of maintenance therapy is to prevent disease progression for as long as possible while maintaining …

Results of a  recent French study demonstrate that a lower dose of thalidomide may be as effective at treating advanced multiple myeloma as a higher dose, with the benefit of fewer side effects.

Due to the reduced side effects observed with lowered thalidomide dosages, researchers conclude that such a regimen may help to improve quality of life in these patients.

Dr. Ibrahim Yakoub-Agha from the University Hospital in Lille, France, and lead author of the study explained to The Beacon that “Given that higher doses of thalidomide are associated with increased toxicity …